TEL AVIV, Israel — November 20, 2025 — Leads & Copy — SciSparc Ltd. (Nasdaq: SPRC) announced today that NeuroThera Labs Inc. (TSXV: NTLX) has advanced its collaboration with Clearmind Medicine Inc. by filing an Israeli patent application for a combination therapy targeting depression.
NeuroThera, a clinical-stage pharmaceutical company in which SciSparc holds a controlling interest of approximately 75%, focuses on developing novel treatments for central nervous system (CNS) disorders. The new patent application is for an innovative therapy that combines 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA).
The therapy is a result of the ongoing collaboration between Neurothera and Clearmind Medicine Inc. (Nasdaq: CMND), and targets depression treatment using the combination of MEAI and PEA. World Health Organization data from August 2025 indicates that major depressive disorder affects approximately 332 million people worldwide, representing an estimated 5.7% of adults globally.
Depression remains one of the leading causes of disability worldwide, contributing significantly to the global burden of disease. The WHO data shows depression is higher among women (6.9%) compared to men (4.6%).
The new filing further expands the joint intellectual property portfolio developed through the collaboration. To date, 13 patents have been filed focusing on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression. Preclinical data supports MEAI’s efficacy in mitigating addictive behaviors while preserving normal natural reward pathways.
SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. SciSparc, together with its majority-owned subsidiary Neurothera Labs Inc., are currently engaged in drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, and SCI-210 for the treatment of ASD and status epilepticus.
NeuroThera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
Investor Contact: IR@scisparc.com, Tel: +972-3-6167055
Source: SciSparc
